Plain-English translation of NCT06531798 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a safety study of Breztri aerosphereTM, an inhaled medication that combines three active ingredients to help manage moderate to severe chronic obstructive pulmonary disease (COPD). The study will track how well patients tolerate this medication and whether it causes any side effects over a 24-week treatment period. About 150 people with COPD will participate.
Even though this medication has already been approved and is being used by patients, the manufacturer wants to gather additional real-world safety information from patients in India to make sure the treatment works well and is safe for this population.
You likely qualify if…
You likely don't qualify if…
You would use the inhaled medication twice a day (two puffs each time) for 24 weeks. The study lasts a total of 26 weeks and includes screening visits at the beginning and follow-up visits throughout to check how you're doing and monitor for any side effects. You would need to be able to use an inhaler device correctly and attend your scheduled appointments.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
India
Phase
Post-approval monitoring
Sponsor
AstraZeneca
Enrollment target
~150 participants
Started
December 2025
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
AstraZeneca Clinical Study Information Center
AstraZeneca
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.